Literature DB >> 34658588

Impact of Intraoperative Tumor Spillage in Uterine Leiomyosarcoma: a Retrospective Single-Institution Analysis.

Viral Patel1, Anupama Rajanbabu1, Indu R Nair2, Pramod R Pillai3, Greeshma C Ravindran4.   

Abstract

Uterine leiomyosarcoma is a rare female reproductive system tumor which is difficult to distinguish from uterine leiomyoma preoperatively. Manual and power morcellation are used to remove the large uterus through the vagina or small abdominal incision. Worse outcome with use of power morcellation is now clear but impact of manual morcellation on survival outcome not established till date. The objective of the present study was to find impact of tumor spillage and to evaluate influencing factors for oncological outcome and prognosis in uterine leiomyosarcoma patients. This is a single-institutional retrospective cohort study including all uterine leiomyosarcoma patients from January 2005 to December 2017. Role of intraoperative tumor spillage and other influencing factors on oncological outcome were assessed. Thirty-three patients with median follow-up period of 49.7 months were evaluated. Stage 1 and absence of tumor spill had significant association with prolonged progression-free survival. Stage 1 uterine leiomyosarcoma (56.8 vs 6.8 months, p =  < 0.001), intraoperative tumor spillage (p = 0.03) and progression-free survival > 15 months (68.5 vs 12.2 months, p =  < 0.001) were favourable prognostic factors to predict better survival outcome but unable to establish significance on multivariate analysis. Survival plot did not reach median limit for stage I uterine leiomyosarcoma patients with preoperative suspicion. Age, site of recurrence and mitotic index had no significant association with better survival in the present study. Stage I disease and absence of tumor spillage during surgery improved progression-free survival but did not affect overall survival. Progression-free survival more than 15 months can predict better overall survival. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Intraoperative tumor spill; Preoperative suspicion for uterine leiomyosarcoma; Uterine leiomyosarcoma

Year:  2021        PMID: 34658588      PMCID: PMC8490543          DOI: 10.1007/s13193-021-01406-5

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  13 in total

1.  Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.

Authors:  Mario M Leitao; Murray F Brennan; Martee Hensley; Yukio Sonoda; Amanda Hummer; Dharmendra Bhaskaran; Ennapadam Venkatraman; Kaled Alektiar; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2002-12       Impact factor: 5.482

2.  FIGO staging for uterine sarcomas.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2009-01-09       Impact factor: 3.561

3.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors:  Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

Review 4.  Uterine sarcomas: a review.

Authors:  Emanuela D'Angelo; Jaime Prat
Journal:  Gynecol Oncol       Date:  2009-10-23       Impact factor: 5.482

5.  Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.

Authors:  Tina Raine-Bennett; Lue-Yen Tucker; Eve Zaritsky; Ramey D Littell; Ted Palen; Romain Neugebauer; Allison Axtell; Peter M Schultze; David W Kronbach; Julia Embry-Schubert; Alvina Sundang; Kimberly Bischoff; Amy L Compton-Phillips; Scott E Lentz
Journal:  Obstet Gynecol       Date:  2016-01       Impact factor: 7.661

6.  Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma.

Authors:  Jose Alejandro Rauh-Hain; Emily M Hinchcliff; Titilope Oduyebo; Michael J Worley; Carolina A Andrade; John O Schorge; Suzanne George; Micheal G Muto; Marcela G del Carmen
Journal:  Int J Gynecol Cancer       Date:  2014-10       Impact factor: 3.437

Review 7.  Uterine leiomyosarcoma: A review of the literature and update on management options.

Authors:  Maureen E Roberts; Jason T Aynardi; Christina S Chu
Journal:  Gynecol Oncol       Date:  2018-09-21       Impact factor: 5.482

8.  Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.

Authors:  Han L T Hoang; Kelsey Ensor; Gerald Rosen; H Leon Pachter; Joseph S Raccuia
Journal:  Int J Surg Oncol       Date:  2014-06-22

9.  Management of uterine sarcomas and prognostic indicators: real world data from a single-institution.

Authors:  Anastasios Kyriazoglou; Michael Liontos; Dimitrios C Ziogas; Flora Zagouri; Kostantinos Koutsoukos; Giorgos Tsironis; Anna Tsiara; Maria Kaparelou; Roubini Zakopoulou; Nikolaos Thomakos; Dimitrios Haidopoulos; Irene Papaspyrou; Alexandros Rodolakis; Aristotelis Bamias; Meletios Athanasios Dimopoulos
Journal:  BMC Cancer       Date:  2018-12-13       Impact factor: 4.430

10.  Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases.

Authors:  E Sun Paik; Jae Hong Kang; Jihye Kim; Yeon-Joo Lee; Chel Hun Choi; Tae-Joong Kim; Byoung-Gie Kim; Duk-Soo Bae; Jeong-Won Lee
Journal:  Obstet Gynecol Sci       Date:  2019-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.